Evidence map›Paper›PMID 38792062›Full record

ArticleMolecules (Basel, Switzerland)2024

Novel Combretastatin A-4 Analogs-Design, Synthesis, and Antiproliferative and Anti-Tubulin Activity.

Marta Jędrzejczyk, Benedetta Morabito, Barbara Żyżyńska-Granica, Marta Struga, Jan Janczak, Maral Aminpour, Jack A Tuszynski, Adam Huczyński

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marta JędrzejczykDepartment of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.
Benedetta MorabitoDepartment of Mechanical and Aerospace Engineering, Politecnico di Torino, 10129 Turin, Italy.
Barbara Żyżyńska-GranicaChair and Department of Biochemistry, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.ORCID 0000-0002-1641-0018
Marta StrugaChair and Department of Biochemistry, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.ORCID 0000-0002-0181-3607
Jan JanczakInstitute of Low Temperature and Structure Research, Polish Academy of Sciences, Okólna 2, 50-422 Wrocław, Poland.ORCID 0000-0001-9826-5821
Maral AminpourDepartment of Biomedical Engineering, University of Alberta, Edmonton, AB T6G 1H9, Canada.
Jack A TuszynskiDepartment of Mechanical and Aerospace Engineering, Politecnico di Torino, 10129 Turin, Italy.ORCID 0000-0001-9976-0429
Adam HuczyńskiDepartment of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.ORCID 0000-0003-4770-215X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combretastatins isolated from the

Indexed as

Cell ProliferationDrug DesignStilbenesTubulinTubulin ModulatorsA549 CellsAntineoplastic AgentsCell Line, TumorDrug Screening Assays, AntitumorHumansMolecular Docking SimulationPolymerizationStructure-Activity RelationshipAntineoplastic AgentsfosbretabulinStilbenesTubulinTubulin Modulatorsantiproliferative activitybinding energycolchicine binding sitecombretastatintubulin-targeting agent

Identifiers

PMID38792062
PMCPMC11124394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.